Key considerations when prescribing midostaurin with a strong CYP3A4 inhibi

https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/56/f2/b8/56f2b88c-f71b-11ca-2fa0-ecddc1044fe8/mza_2145894122309428224.jpg/600x600bb.jpg

MediCom Oncology Clinical Pearls Podcasts

MediCom Oncology

53 episodes

1 month ago

Dr. Perl provides a brief summary of what is on the horizon for FLT3 inhibitors in AML.

Science

RSS

All content for MediCom Oncology Clinical Pearls Podcasts is the property of MediCom Oncology and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Dr. Perl provides a brief summary of what is on the horizon for FLT3 inhibitors in AML.

Science

https://i1.sndcdn.com/artworks-000415463430-t33rsc-t3000x3000.jpg

Key considerations when prescribing midostaurin with a strong CYP3A4 inhibi

MediCom Oncology Clinical Pearls Podcasts

2 minutes 23 seconds

7 years ago

Key considerations when prescribing midostaurin with a strong CYP3A4 inhibi

Dr. Perl gives guidance on providing optimal patient therapy when prescribing midostaurin with a strong CYP3A4 inhibitor.